ArticleNeuropsychopharmacology reports2025
A Japanese Pregnant Woman With Treatment-Resistant Schizophrenia Who Continued Clozapine With Blood Concentration Monitoring During the Perinatal Period and Had a Healthy Baby: A Case Report.
Article in Neuropsychopharmacology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClozapine is known to improve the social functioning of patients with treatment-resistant schizophrenia (TRS). In Japan, there are few reports on pregnancy and childbirth in patients treated with clozapine, and information on its effects on the fetus and mother is limited. CASE PRESENTATION: A woman in her 30s with TRS planned her pregnancy while using clozapine (300 mg/day). From around 32 weeks of gestation, she noticed decreased fetal movement and fetal heart rate abnormalities were observed. At 35 weeks of gestation, her clozapine blood concentration was 594 ng/mL (clozapine blood concentration/clozapine dose: C/D ratio, 1.98), which was slightly high, so the dose was reduced to 275 mg/day. With the continuation of clozapine, the mother's psychiatric symptoms remained stable, and she delivered a healthy baby vaginally at 38 weeks of gestation. The clozapine blood concentration increased just before delivery (C/D ratio 2.35) but rapidly decreased after delivery (C/D ratio 1.69). The newborn was discharged in good condition on the fourth day of life.
conclusionThis case suggests that clozapine can contribute to pregnancy and live birth in TRS patients, but the blood concentration of clozapine may increase more than expected in late pregnancy, necessitating consideration of dose reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.